Incidence and predictors of spontaneous thyroid-stimulating hormone normalization after lobectomy for low-risk papillary thyroid microcarcinoma: evidence from contemporary clinical practice - Report - MDSpire
Advertisement
Incidence and predictors of spontaneous thyroid-stimulating hormone normalization after lobectomy for low-risk papillary thyroid microcarcinoma: evidence from contemporary clinical practice
Predictors and Frequency of Spontaneous Normalization of TSH Levels
Overview
This study investigates the spontaneous normalization of thyroid-stimulating hormone (TSH) levels in patients with low-risk papillary thyroid microcarcinoma (PTMC) post-lobectomy. It identifies preoperative predictors, revealing that a preoperative TSH ≤ 1.7 μIU/mL is a significant indicator for achieving TSH normalization within one year.
Background
Thyroid cancer, particularly papillary thyroid carcinoma (PTC), is the most rapidly increasing endocrine malignancy globally. Management strategies for low-risk PTC, including lobectomy, are evolving. Understanding the predictors of TSH normalization can help tailor postoperative management.
Data Highlights
Time Point
Spontaneous TSH Normalization Rate
0.5 months
32.4%
1.5 months
20.2%
6 months
14.8%
12 months
12.4%
Key Findings
Spontaneous TSH normalization rates decreased over time: 32.4% at 0.5 months to 12.4% at 12 months.
Patients achieving spontaneous normalization at 12 months were younger and had higher preoperative fT3 levels.
A preoperative TSH level of ≤ 1.7 μIU/mL was identified as an independent predictor of TSH normalization.
TSH target achievement with thyroid hormone therapy reached 100% at 12 months.
Clinical Implications
The findings indicate that preoperative assessment of TSH levels can inform management decisions regarding levothyroxine therapy in low-risk PTMC patients.
Conclusion
The study highlights the potential for spontaneous TSH normalization in low-risk PTMC patients post-lobectomy, with a preoperative TSH level of ≤ 1.7 μIU/mL serving as a predictor.
